Key Points
- CEO Joel Lewis sold 7,829 shares at an average price of $7.06 on Dec. 17 (≈$55,273), trimming his stake to 832,592 shares (~$5.88M); multiple insiders and a major shareholder also sold large blocks, which likely pressured the share price.
- Regulatory and financing update: the FDA’s written response aligned with Galectin on the proposed belapectin registration trial population, and the company secured a $10M unsecured convertible line of credit from its chairman, which management says funds operations into at least March 2027.
- Stock and analyst context: GALT is trading near $4.38 (down ~28.9%), with a 52‑week range of $0.73–$7.13 and a ~$282M market cap; the company is loss-making, analysts are mixed (HC Wainwright raised its target to $11) and consensus sentiment is a Hold.
Galectin Therapeutics Inc. (NASDAQ:GALT - Get Free Report) CEO Joel Lewis sold 7,829 shares of the stock in a transaction on Wednesday, December 17th. The stock was sold at an average price of $7.06, for a total value of $55,272.74. Following the sale, the chief executive officer directly owned 832,592 shares of the company's stock, valued at approximately $5,878,099.52. This represents a 0.93% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
Joel Lewis also recently made the following trade(s):
- On Wednesday, November 5th, Joel Lewis sold 200 shares of Galectin Therapeutics stock. The shares were sold at an average price of $6.00, for a total transaction of $1,200.00.
- On Tuesday, November 4th, Joel Lewis sold 14,420 shares of Galectin Therapeutics stock. The stock was sold at an average price of $6.07, for a total transaction of $87,529.40.
- On Monday, November 3rd, Joel Lewis sold 1,300 shares of Galectin Therapeutics stock. The stock was sold at an average price of $6.01, for a total transaction of $7,813.00.
Galectin Therapeutics Stock Down 28.9%
Shares of NASDAQ:GALT opened at $4.38 on Friday. Galectin Therapeutics Inc. has a fifty-two week low of $0.73 and a fifty-two week high of $7.13. The firm's 50-day simple moving average is $5.57 and its 200-day simple moving average is $4.17. The company has a market cap of $282.38 million, a price-to-earnings ratio of -7.42 and a beta of 0.95.
Galectin Therapeutics (NASDAQ:GALT - Get Free Report) last posted its quarterly earnings results on Friday, November 14th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.02). On average, research analysts forecast that Galectin Therapeutics Inc. will post -0.73 EPS for the current year.
Wall Street Analysts Forecast Growth
Several brokerages have weighed in on GALT. Weiss Ratings restated a "sell (d-)" rating on shares of Galectin Therapeutics in a research report on Wednesday, October 8th. HC Wainwright lifted their price objective on Galectin Therapeutics from $6.00 to $11.00 and gave the stock a "buy" rating in a research report on Wednesday. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company has an average rating of "Hold" and a consensus target price of $11.00.
Check Out Our Latest Stock Analysis on GALT
Key Stores Impacting Galectin Therapeutics
Here are the key news stories impacting Galectin Therapeutics this week:
- Positive Sentiment: FDA written response aligns with the company on the proposed patient population for a registration trial of belapectin and the company will pursue a follow‑up Type C meeting to finalize trial design; management says new biomarker data will be presented. This reduces some regulatory uncertainty for the lead program. Galectin Therapeutics Provides Regulatory Update
- Positive Sentiment: Galectin secured a $10M unsecured, convertible line of credit from its chairman and extended maturities on related notes, which management says funds operations into at least March 2027 — a near‑term liquidity buffer while belapectin development continues. Regulatory update & financing
- Neutral Sentiment: Technically, the stock recently crossed above its 200‑day moving average — a bullish technical sign for some traders, but not a fundamental change. Shares Cross Above 200-Day Moving Average
- Negative Sentiment: Significant insider selling: multiple insiders (CEO Joel Lewis, Director Harold H. Shlevin, CMO Khurram Jamil) sold large blocks of stock on Dec. 16–17 at prices in the $6.66–$7.06 range — and a major shareholder (Fund L.P. 10X) also sold ~30,681 shares. The concentrated selling likely pressured the share price despite the regulatory/financing news. Insider Selling: Galectin Therapeutics
- Negative Sentiment: While HC Wainwright maintained a Buy and raised its price target to $11 (from $6), analyst optimism can be slower to offset immediate selling pressure from insiders and short‑term traders. HC Wainwright maintains Buy, raises target
Institutional Trading of Galectin Therapeutics
Several institutional investors have recently made changes to their positions in GALT. JPMorgan Chase & Co. increased its holdings in shares of Galectin Therapeutics by 25.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 15,470 shares of the company's stock worth $66,000 after buying an additional 3,133 shares during the last quarter. Retirement Guys Formula LLC boosted its holdings in Galectin Therapeutics by 2.7% in the second quarter. Retirement Guys Formula LLC now owns 159,593 shares of the company's stock valued at $337,000 after acquiring an additional 4,250 shares during the last quarter. Stratos Wealth Partners LTD. grew its position in Galectin Therapeutics by 17.8% during the second quarter. Stratos Wealth Partners LTD. now owns 60,750 shares of the company's stock valued at $128,000 after acquiring an additional 9,200 shares during the period. Atwood & Palmer Inc. acquired a new stake in Galectin Therapeutics during the third quarter worth about $42,000. Finally, Archer Investment Corp acquired a new stake in Galectin Therapeutics during the third quarter worth about $47,000. 11.68% of the stock is owned by hedge funds and other institutional investors.
Galectin Therapeutics Company Profile
(
Get Free Report)
Galectin Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel therapies that target galectin proteins, which are implicated in fibrotic, inflammatory and malignant diseases. The company's lead product candidate, belapectin (formerly GR-MD-02), is a galectin-3 inhibitor being evaluated in Phase 2 clinical trials for nonalcoholic steatohepatitis (NASH) with cirrhosis. In addition to its core pipeline in fibrotic liver disease, Galectin Therapeutics continues to explore the potential of its galectin inhibitors in oncology and other indications driven by abnormal tissue remodeling.
Founded in 2000, the company is headquartered in Norcross, Georgia, where it oversees discovery research, preclinical studies and clinical trial coordination.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
